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ABSTRACT 
Leishmaniasis is a parasitic disease remaining a major public health problem. It causes 
illness and death especially in developing countries. Common chemotherapeutic agents currently 
used are often inadequate, requiring long courses of parenteral administration, having toxic side 
effects or becoming less effective due to the emergence of resistant strains. Thus, there is an 
urgent need for new, effective, and inexpensive drugs. 
In the fight against leishmaniasis, natural products are important sources of novel 
therapeutic agents. The goal of our research is to study secondary metabolites from endophytic 
fungi as a source of effective antileishmanial agents. Many crude extracts from endophytic fungi 
have been screened for antiparasitic activity against Leishmania donovani and Plasmodium 
falciparum. The active samples were further evaluated regarding their toxicity versus 
mammalian cell lines. From the results, DC401 was identified as a promising source of new 
antiparasitic compounds.   
Biotransformation is defined as the use of biological systems to modify substances that 
are not used for growth. The process leads to a modified chemical structure and therefore a 
change in activity of the biotransformed compound, if the activity and structure are correlated. 
The bioassay-guided fractionation of Limonium myrianthum resulted in the isolation of 
5,7,2',4',5'- pentahydroxyflavonol. This compound possessed significant antifungal activity  
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against the fungal pathogens Candida glabrata and Candida krusei at IC50 4.44 and 9.56 µg/mL, 
respectively. Biotransformation of 5,7,2',4',5'- pentahydroxyflavonol compound was done in an 
attempt to improve its biological activity.  
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1. Introduction 
Nature has developed by time to produce a diversity of pharmaceutical secondary active 
metabolites. According to the World Health Organization (WHO), 80% of the world’s human 
population relies on traditional medicine for their healthcare. In developing countries plants are 
the main sources of medicine; therapies based on these plants often have minimal side effects. 
Traditional herbal medicines are an affordable choice for the people in the developing countries 
because of the relatively high cost of synthetic medicines. In the Western world, the plant-
derived medicines are supplanted by pharmaceutical ingredients[1, 2]. World business in plant 
medicines is in billions of dollars[3]. Natural products are produced by all organisms but are 
mostly known from plants and microorganisms including fungi and prokaryotes[4]. The most 
recent survey of molecules discovered post-1970, covering the period 1981-June 2006, lists a 
total of 1184 new chemical entities receiving approval as pharmaceutical drugs. 52 % of these 
have a natural product connection, 18% are biologics, and 30% are purely synthetic[5]. Ganesan 
et al. (2008) had done meta-analysis of those compounds that reveals a total of 24 unique natural 
product chemotypes that led at least to one approved drug. Among the 24 leads progressed to 
approved drugs with no modification. Other six natural products were modified by semi- 
synthesis [2]. Furthermore, a significant number of the top 35 worldwide selling drugs in the 
years 2000-2003 was natural product-derived compounds[6]. Natural products often serve as 
lead structures whose activity can be improved by manipulation through combinatorial and 
synthetic chemistry. Since there are still many unexplored resources in nature, the potential for 
finding new pharmaceutical compounds is still tremendous[7].
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1.1. Endophytes   
De Bary (1866) was the first person who introduced the term “epiphytes” for fungi that 
live on the surface of their host and “endophytes” for those living inside the plant tissue[8]. 
Fungi producing the visible symptoms of plant disease are eliminated from endophyte category, 
although all pathogenic fungi penetrate the host tissue and exist endophytically, and fungi that do 
not cause any visible disease symptoms within the tissues of the host plants are endophytes. 
Fungi that inhibit plant organs at some point in their life cycle without causing apparent harm to 
their host are included in the endophyte category[9, 10].  
 
1.2. The impact of fungal natural products in drug discovery 
Fungi were found to produce a wide range of pharmaceutically significant compounds 
that belong to different chemical classes. A number of important pharmaceutical substances have 
been isolated and identified from fungi[11]. After Fleming in 1928 discovered the fungal 
metabolite penicillin and its development as antibiotic drug, fungal secondary metabolites have 
been an important source for new pharmaceutical and drug lead compounds[7, 12]. About 20 
years later several other antibacterial agents such as cephalosporin C had been derived from 
the fungus Acremonium[13] . Soon thereafter, many antimicrobial compounds have been isolated 
from fungi. For example, griseofulvin which has been used for the systemic treatment of fungal 
infections of skin, hair, and nails was first isolated from the Penicillium griseofulvum[14]. 
Cryptocandin is a unique antifungal peptide isolated from the endophytic fungus 
Cryptosporiopsis cf. quercina isolated from Tripterigeum wilfordii which is a medicinal plant 
native to Eurasia[15]. Jesterone is an antifungal compound isolated from the fungus 
Pestalotiopsis jester which also produces hydroxyjesterone[16]. Cryptocin is a potent antifungal
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compound which is a unique tetramic acid isolated from Cryptosporiopsis cf. quercina[17]. 
Another antifungal compound phomopsilactone was isolated from Phomopsis casiae[18]. 
Phomopsichalasin was isolated and characterized from Phomopsis sp. It has both the 
antibacterial and antifungal properties[19]. Pestaloside is an aromatic B-glucoside isolated from 
Pestalotiopsis microspora. It is reported as an antifungal agent. 
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Figure 1: Fungal natural products with antimicrobial activity 
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  Similarly, cyclosporine was isolated from Tolypocladium inflatum, in 1971 and was 
routinely used as immunosuppressant during organ transplantations[6, 20, 21]. It is now widely 
used in organ and tissue transplant surgery to prevent rejection following bone marrow, kidney, 
liver, and heart transplants. It has revolutionized organ transplantations and has been increasing 
survival rates in transplant patients[22]. Mycophenolic acid, isolated from Penicllium, 
Aspergillus, Byssochlamys, and Septoria species, is another strongly immunosuppressive fungal 
metabolite used for organ transplant surgery and for treatment autoimmune diseases[12, 23]. 
Subglutinol A and B were isolated from the endophyte Fusarium sublutinans. Both are nontoxic 
and very potent in the mixed lymphocyte reaction (MLR) and thymocyte proliferation (TP) 
assays[24].   
 
 
Figure 2: Immunosuppressive fungal metabolites 
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Taxol, very potent anticancer agent, was first isolated from the bark of the Pacific Yew 
(Taxus brevifolia)[25]. It stabilizes microtubule formation because it binds to a specific binding 
site on the microtubule polymer. It was approved by Food and Drug Administration (FDA) for 
the treatment of ovarian and breast cancer[26]. Taxol is a complex molecule difficult to be 
chemically synthesized and its chemical synthesis is not very economical. The Taxus genus 
produces very little amout of Taxol so researchers were searching for this compound from other 
sources. Endophytic fungus Taxomyces andreanae, isolated from the plant Taxus brevifolia, was 
found to produce taxol[27].  Taxol has also been isolated from other endophytic species, 
Pestalotiopsis microspora isolated from Taxus wallichi[28, 29]; Pestalotiopsis guepini isolated 
from Wollemi pine[30]; and Tubercularia sp. Isolated from the Chinese yew (Taxus mairei)[31]. 
Torreyanic acid, another anticancer agent, was isolated from endophyte Pestalotiopsis 
microsporum starin. It is very potent cytotoxic agent and was found 5- 10 times more potent in 
cell lines that are sensitive to protein kinase C agonists. It causes cell death by apoptosis[32]. 
 
Figure 3: Anticancer fungal metabolites 
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Other important drugs are the fungal derived statins. Statins are the most potent 
cholesterol-lowering agents available. They are either isolated from endophytic fungi such as 
mevastatin and lovastatin (Mevacor
®
), from Penicillium citrinum and Aspergillus terreus 
respectively, or synthetic analogue compounds such as the major selling synthetic statins 
(lipitor
®
 , crestor
®
 , and Zocor
®
). The mechanism of action of statins is by reversible competitive 
inhibition of the rate-limiting enzyme HMG-CoA reductase in the mevalonate pathway of 
cholesterol biosynthesis, reducing total and low-density lipoprotein cholesterol levels. Statins are 
of potential value in treating high-risk coronary patients because high blood cholesterol levels 
contribute to the incidence of coronary heart diseases[6, 22]. Two lipid-regulating drugs of this 
class, atrovastatin (Lipitor
®
) and simvastatin (Zocor
®
), are ones of the best selling drugs in 
pharmaceutical history.  
 
Figure 4: Fungal and synthetic analogues of antilipidemic statin compounds 
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1.3. Compounds from Fungi in Clinical Trials 
There are two fungal-derived molecules that serve as templates for analogs used in 
clinical trials, fumagillin and illudin S[33]. Fumagillin is isolated from the fungus Aspergillus 
fumigatus and is an angiogenesis inhibitor which suppresses the formation and growth of new 
blood vessels, the angiogenesis, by direct blocking endothelial cell proliferation[34, 35]. 
Fumagillin has been the template for analogues undergoing oncological clinical trials [35].  
Semi-synthetic derivatives, such as  TNP-470, PPI-2458 and CKD-732 entered clinical trials for 
the treatment of brest, prostate, Kaposi sarcoma, and brain cancer [35-40]. The mechanism of 
action of TNP-470 is an irreversible binding to methionine aminopeptidase 2 which leads to 
intracellular signaling interference[41, 42]. Clinical trials of PPI-2458 were later terminated in 
this use[43]. PPI-2458 has been investigated for the treatment of rheumatoid arthritis. Moreover, 
fumagillin has been proven to be highly active as antimicrosporidial agent in mice[44] and has 
been found to inhibit HIV-1 viral protein R (VPR) activity[45]. Remarkably, fumagillin was 
approved for use in the treatment of intestinal microsporidiosis in France in 2005, a disease 
caused by the parasite Enterozytozoon bieneusi, which is of major concern to 
immunocompromised patients as it can cause diarrhea[46]. 
Illudin S is another anticancer lead compound of fungal origin. It was first isolated from 
Omphalotus illudens and was shown to be cytotoxic against the human leukemia cell line HL-60 
in vitro (IC50 = 3 ng/mL), but exhibiting a low therapeutic index in mouse xenograft solid tumor 
systems[47-49]. Irofulven is the improved semi-synthetic compound and has a significantly 
superior therapeutic index in comparison to the parent natural product illudin S and has 
selectivity towards human tumor cells in which apoptosis is induced. It shows an IC50 value of 
73 nM in MV522 lung cell assay with only a marginal apoptotic effect on normal human 
10 
 
cells[50-52]. Irofulven has a greater efficacy than illudin S because of its slower and more 
selective action. It has entered phase I and II clinical trials against several types of cancer[53]. 
 
Figure 5: Fungal metabolites in clinical trial 
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2. Leishmaniasis 
 
2.1. History of the Disease 
Leishmania parasites in a specimen from a “Delhi boil”, a Visceral Leishmaniasis (VL), 
were first identified by Cunningham in 1885 in India. Shortly after that, the Russian army 
surgeon Borovsky gave a good description of the organisms in lesions from a “Sart sore” 
observed in Tashkent, Uzbekistan in 1889. In 1903, Wright, an American physician, discovered 
intracellular protozoal organisms inside a cutaneous lesion from a young Armenian immigrant. 
The organisms were named “Helcosoma tropicum” by Wright. Similar organisms which were 
found in the spleens of “Kala-azar” patients were studied independently by Leishman and 
Donovan in 1903. They were later named Leishmania donovani by Ross in 1903. The organisms 
were found by Wright were named Leishmania tropica by Lühe in 1906[54].   
 
2.2. Parasite Transmission and Life Cycle 
  Leishmaniasis is a spectrum of disease caused by protozoan parasites belonging to the 
genus Leishmania. There are twenty pathogenic Leishmania species for human. They can be 
transmitted by the bit of an infected female sandfly introducing parasites into the host. There are 
thirty sandfly species proven vectors. They can become infected when taking a blood meal from 
a reservoir host. Hosts are infected humans and wild and domestic animals. Epidemiologically, 
the transmission cycle can be zoonotic, meaning animal reservoir hosts are
12 
 
involved, or anthroponotic, where man is the sole source of infection for the insect vector. The 
life cycle of Leishmania (Figure 6) involves two parasite forms, the flagellated motile 
promastigote stage inhabiting the gut of the sandfly, and the non flagellated amastigote stage 
growing inside the phagolysosomes of mammalian macrophages[55, 56]. 
 
 
Figure 6: Life Cycle of Leishmania 
(Reproduced by permission of the Centers for Disease Control and Prevention) 
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2.3. Clinical Manifestations 
     The clinical manifestations of the disease depend on the infecting species. 
Leishmaniasis presents itself in three main clinical forms which have devastating consequences. 
In visceral Leishmaniasis (VL or “kala-azar”), the parasites reside in the liver, spleen, and bone 
marrow causing a severe systemic disease which is fatal if it is not treated. Mucocutaneous 
Leishmaniasis (MCL) is characterized by lesions in the mucous tissues of the nose and mouth 
and often progresses to massive tissue destruction and disfigurement. Cutaneous leishmaniasis 
(CL) involves the development of self-healing but chronic skin ulcers at the site of sandfly bites. 
There are also two rare types, post kala-azar dermal leishmaniasis (PKDL) and viscerotropic 
leishmaniasis. PKDL is a chronic CL form that develops in some patients after recovering from 
VL.  Viscerotropic leishmaniasis is a mild visceral disease that does not progress to classic kala-
azar. Viscerotropic leishmaniasis was observed in nine veterans (out of 500,000 U.S. soldiers) of 
first Gulf War. Symptoms varied including, fevers, chronic fatigue, malaise, cough, intermittent 
diarrhea, or abdominal pain[57].      
 
2.4. Epidemiology 
The epidemic of VL in southern Sudan in the early 1990s resulted in an estimated overall 
death rate of 38-57% and up to 70% in the most affected areas, corresponding to about 100,000 
deaths among approximately 280,000 people in the epidemic area[58]. According to World 
Health Organization (WHO) statistics[59], there are 12 million people currently affected by 
leishmaniasis in 88 countries on five continents- Africa, Asia, Europe, North America, and South 
America- with a total of 350 million people at risk. Two million new cases, 1.5 million for CL 
and 500,000 for VL, are considered to occur annually. 90% of VL cases reside in five countries: 
Bangladesh, India, Nepal, Sudan, and Brazil, while 90% of CL cases occur in seven countries: 
14 
 
Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia, and Syria. It seems to be an increased 
incidence over the past decade; e.g. CL in Brazil: 1998, 21,800 cases; 2002, 40,000 cases and CL 
in Kabul, Afghanistan: 1994, 14200; 2002, 65,000 cases. The reasons for this include rural to 
urban migration, projects bringing non-immune populations to endemic areas, malnutrition that 
decreases immunity, socioeconomic deterioration in crowded poor city suburbs, and the 
emergence of leishmaniasis/HIV co-infection. Nevertheless, there is little doubt that the actual 
prevalence of leishmaniasis is considerably greater than the numbers officially reported because 
many cases go either undiagnosed or unreported, especially in places where patients have no 
access to medical facilities. Additionally, the economic impact of the disease is huge, with the 
serious costs involved (medical care/treatment, depletion of work force) negatively affecting the 
implementation of development projects[60]. In short, the situation is worsening and the progress 
being made against the disease is disappointing[61].  
 
2.5. Leishmaniasis in the Western Nations  
The leishmaniases have been considered as diseases of tropical and subtropical countries. 
The WHO lists leishmaniasis as one of the six most important tropical diseases. Nevertheless, 
there is a growing interest in this disease in industrialized countries due to the increase of 
Leishmania-HIV co-infection[62] and the increased importance of travel medicine. Moreover, 
leishmaniasis is an emerging zoonosis in the U.S.A.[63-65] and 500-700 parasitologically 
confirmed cases were identified in U.S. soldiers in the Middle East between 2002-2004[66, 67].  
In addition, immunologists have studied Leishmania species as interesting models of intracellular 
parasitism where a microorganism survives and multiplies within macrophages[56]. 
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2.6. Control and Chemotherapy 
Control of leishmaniasis remains a serious problem. Transmission is difficult to interrupt. 
Some attempts to reduce vector and mammalian reservoir populations have been successful. No 
vaccines are available for either VL or CL up to today inspite of various research efforts.[68] 
Available drugs are limited in number and suffer from various shortcomings. [57, 69-74] 
Pentavalent antimonials, sodium stibogluconate (Pentostam
TM
, Wellcome) (Figure 7) and 
meglumine antimonate (Glucantime
TM
, Farmitalia) have been the first line drugs for over 50 
years. They require long courses with parental administration and have toxic side effects and 
variable efficacy. Increasing resistance to antimonials is observed, specifically in northeast 
India[72]. The second treatment is amphotericin B (Figure 7). It is given parenterally and has 
considerable renal toxicity. Newer agents with proven efficacy against Indian visceral disease 
include liposomal amphotericin B which is easily tolerated and requires fewer injections and the 
oral agent miltefosine (Figure 7). The former agent suffers from its high cost and the latter is 
extremely teratogenic[74]. So, there is an urgent need for new drugs against leishmaniasis.    
 
16 
 
 
Figure 7: Antileishmanial drug
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3. Result and Discussions 
Endophytic fungi sent to us by our colleague from University of Arizona were cultured 
on small scale and extracted. The extracts were screened for antimicrobial, antileishmanial, and 
antimalarial activity at the National Center for Natural Products Research at the University of 
Mississippi.                                                                                                                                                                   
3.1. Preliminary Data 
3.1.1.  Antibacterial and Antifungal Data 
 
 
Concentration: 50µg/ml. 1Samples showing % Growth Inhibition < 50 are considered inactive.   
2Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay
 
Table 1: ANTIMICROBIAL ACTIVITY REPORT- PRIMARY 
 
% Growth Inhibition
1,2 
Anti-Fungal  Anti-Bacterial  
Sample  C. 
albicans 
C. 
glabrata 
C.  
krusei 
A. 
fumigatus 
C. 
neoformans 
 
S.  
aureus 
MRS E. 
coli 
P.  
aerug 
M. 
intracellulare 
9002 11 2 11 0 44 100 100 33 9 7 
9201 7 4 12 37 68 0 0 0 0 8 
9121 1 28 5 0 0 0 0 8 0 0 
DC656 2 5 13 0 6 13 10 0 0 0 
6239 3 7 10 0 21 37 51 0 8 0 
6263 1 0 15 0 5 10 5 0 0 3 
DC 12 24 4 12 0 30 6 8 0 10 63 
DC486 65 100 49 14 0 14 14 0 2 0 
5952 55 62 76 0 100 14 13 0 0 0 
DC462 9 8 6 0 18 0 5 7 0 0 
DC299 5 19 27 10 0 4 2 34 0 0 
2123 5 8 22 0 9 39 55 26 12 0 
6075 5 2 13 0 13 100 100 65 15 0 
9298 3 0 18 0 5 0 1 6 0 0 
6360 0 0 12 0 0 0 30 18 2 0 
9121 a 7 0 8 0 0 6 6 0 0 0 
6060 8 0 15 0 0 11 10 0 1 0 
11321 0 2 23 11 13 0 11 6 1 26 
DC401 0 28 30 10 23 100 99 4 0 29 
18 
 
 
 
 
Concentration: 50 µg/ml 
1Samples showing % Growth Inhibition < 50 are considered inactive  
2Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
 
     As shown in Table 1 and Table 2, the extracts were inactive against most of the 
microorganisms (less than 50% growth inhibition) while some extracts (bolded and underlined) 
showed activity (greater than or equal to 50% growth inhibition) against C. albicans, a yeast that 
 Table 2: ANTIMICROBIAL ACTIVITY REPORT- PRIMARY 
% Growth Inhibition
1,2 
Anti-Fungal  Anti-Bacterial  
Sample  C. 
albicans 
C. 
glabrata 
C.  
krusei 
A. 
fumigatus 
C. 
neoformans 
S. 
aureus 
 
MRS 
E. 
coli 
P.  
aerug 
M. 
intracellulare 
JO 61 0 58 61 16 0 10 14 16 4 0 
LGO125 0 6 33 8 4 4 3 8 0 0 
LG0011 0 16 24 8 10 0 1 15 0 0 
DC3043 0 18 17 6 0 0 0 4 0 1 
JO 184 0 10 20 5 5 0 14 14 0 0 
11310 0 12 27 8 13 0 1 10 0 0 
11076 0 22 24 8 17 13 21 1 0 0 
JM0070 0 30 27 24 81 0 0 17 0 14 
DC3412 0 9 36 12 8 0 0 17 0 0 
LG0038 0 18 21 4 8 39 2 14 0 0 
DC3530 17 22 23 0 42 0 0 18 0 0 
DS0046 21 14 0 0 41 35 0 35 0 0 
11060 26 57 35 29 45 6 7 15 0 0 
DC3487 19 10 14 1 41 0 0 9 0 0 
11144 35 40 39 0 100 98 99 36 0 0 
JO 58 18 40 29 0 26 4 2 9 0 0 
JO 55 15 38 29 10 25 0 3 19 0 0 
11078 0 42 18 5 8 11 0 16 1 0 
DS0014 0 0 5 5 28 5 0 0 1 0 
R 03 14 45 22 21 38 66 64 20 15 0 
11295 0 0 4 6 27 2 0 17 1 0 
R 04 0 0 4 6 24 2 0 1 3 0 
JO 129 0 0 11 4 19 1 0 0 0 0 
R 02 0 0 5 3 12 1 0 0 0 0 
S 01 0 0 8 6 8 7 0 1 0 0 
DS 0035 0 0 11 7 19 8 0 8 3 0 
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is a causal agent of  opportunistic oral and genital infections in humans; C. glabrata, a yeast a 
highly opportunistic pathogen of the urogenital tract, and of the bloodstream especially prevalent 
in HIV positive people and the elderly; C. krusei, an emerging fungal nosocomial pathogen 
primarily found in the immunocompromised and those with hematological malignancies;  C. 
neoformans,a yeast associated with lung infections and fungal meningitis; MRS, Methicillin-
resistant Staphylococcus aureus, a bacterium esponsible for several difficult-to-treat infections in 
humans; S. aureus, a bacterium that can cause a range of illnesses, from minor skin infections, 
such as pimples, impetigo, boils (furuncles), cellulitis folliculitis,carbuncles, scalded skin 
syndrome, and abscesses, to life-threatening diseases such as pneumonia,  meningitis, 
osteomyelitis,  endocarditis, and toxic shock syndrome (TSS).  Those extracts showing activity 
were moved forward for secondary screening. 
 
“-“= Not Active. Concentration:  50, 10, 2g/ml. For extracts & column fractions we consider an IC50 < 20 g/ml active. 
 
 
 
 
Table 3: ANTIMICROBIAL ACTIVITY REPORT- SECONDARY 
*IC 50 
Anti-Fungal  Anti-Bacterial  
Sample C. 
albicans 
C. 
glabrata 
C. 
krusei 
A. 
fumigatus 
C. 
neoformans 
 
S. 
aureus 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9002 - - - - 18.86 1.74 < 2 - - - 
9201 - - - 23.05 18.34 - - - - - 
6239 - - - - - - 33.6 - - - 
DC486 - - - - - - - - - - 
5952 - - - - - - - - - - 
2123 33.73 8.27 - - - - - - - - 
6075 - 19.75 - - 3.34 < 2 < 2 16.18 - - 
DC401 - - - - - 40.6 16.59 - - - 
JO 61 - 31.65 13.95 - - - - - - - 
JM0070 - 50 50 - < 2 - - - - - 
11060 - 10.82 45.17 - - - - - - - 
11144 - 2 8.04 - 11.09 < 2 < 2 - - - 
R 03 - 10.48 - - - 50 > 50    
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Microorganism Drug Control IC50 (g/ml)
* 
MIC (g/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.20 0.63 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.25 0.63 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.51 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.10 2.50 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.42 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.17 0.50 
Methicillin-resistant S. aureus ATCC 43300 
(MRS) 
Ciprofloxacin 0.09 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.006 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.082 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.36 0.50 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
The secondary assay screening was done at three concentrations (50, 10, and 2 µg/ml). 
The IC50 values that are reported here represent the concentration (µg/ml) that affords 50% 
growth inhibition (Table 3). Those samples whose IC50 values were less than the lowest 
concentration tested (< 20 µg/ml) were retested at lower concentrations.    
 
“-“= Not Active 
Concentration:  50, 10, 2, 0.4, 0.08, 0.016g/ml 
For extracts & column fractions we consider an IC50 < 20g/ml active 
*The concentration (g/ml) that affords 50% inhibition of growth 
 
 
 
 
 
 
 
 
Table 4: ANTIMICROBIAL ACTIVITY REPORT- TERTIARY 
*IC 50 
Anti-Fungal  Anti-Bacterial  
Sample C. 
albicans 
C. 
glabrata 
C. 
krusei 
A. 
fumigatus 
C. 
neoformans 
 
S. 
aureus 
MRS E. 
coli 
P. 
aerug 
M. 
intracellulare 
9002 - - - - 50 2.75 4.46 - - - 
6075 10.87 - 27.24 - 10.19 0.50 0.58 12.66 - - 
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Microorganism Drug Control IC50 (µg/ml)* MIC(µg/ml)** 
C. albicans ATCC 90028 (Ca) Amphotericin B 0.20 0.63 
C. glabrata ATCC 90030 (Cg) Amphotericin B 0.25 0.63 
C. krusei ATCC 6258 (Ck) Amphotericin B 0.51 1.25 
A. fumigatus ATCC 90906 (Afu) Amphotericin B 1.10 2.50 
C. neoformans ATCC 90113 (Cn) Amphotericin B 0.42 0.63 
S. aureus ATCC 29213 (Sa) Ciprofloxacin 0.17 0.50 
Methicillin-resistant S. aureus ATCC 43300 
(MRS) 
Ciprofloxacin 0.09 0.25 
E. coli ATCC 35218 (Ec) Ciprofloxacin 0.006 0.016 
P. aeruginosa ATCC 27853 (Pa) Ciprofloxacin 0.082 0.250 
M. intracellulare ATCC 23068 (Mi) Ciprofloxacin 0.36 0.50 
*The concentration (g/ml) that affords 50% inhibition of growth 
**MIC (Minimum Inhibitory Concentration is the lowest concentration (g/ml) that allows no detectable growth 
 
In the tertiary assay, samples were tested at six concentrations, 50, 10, 2, 0.4, 0.08, 0.016 
µg/ml. IC50 values are shown in Table 4. None of the reported IC50 values were less than the 
drug controls.  
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3.1.2.  Antileishmanial data 
Table 5: ANTI-LEISHMANIA SCREENING ASSAYS-PRIMARY DATA 
Sample Name Leishmania donovani % inhibition 
9002 96.08 
9201 55.95 
9121 NA 
DC 656 64.42 
6239 95.20 
6263 NA 
DC 12 99.53 
DC 486 3.49 
5952 NA 
DC 462 NA 
DC 299 NA 
2123 9.27 
6075 NA 
9298 NA 
6360 14.80 
9121 a 54.81 
6060 NA 
DC 401 98.59 
9165 NA 
1971 NA 
 DC 1010 NA  
6086 NA 
DC 653 6.51 
DC 10  NA  
DC 19 NA  
1850 NA 
6141 NA 
1894 NA 
1907 NA 
DC 38 NA 
DC 52 NA 
9187 NA 
9198 NA 
9121 b 98.91 
Test concentration: 80 µg/ml 
NA= Not Active 
Samples showing % Growth Inhibition < 50 are considered inactive  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
Drug Control % Inh 
Amph B 100.0 
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Table 6: ANTI-LEISHMANIA SCREENING ASSAYS-PRIMARY DATA 
Sample Name Leishmania donovani % inhibition 
2162 NA 
9189 NA 
6152 NA 
9209 NA 
11321 34.7 
JO 61 65.7 
LG 0125 A 22.5 
LG 0011 47.6 
DC 3043 7.5 
JO 184 27.5 
11310 17.2 
11076 18.5 
JM 0070 37.4 
DC 3412 11 
LG 0038 54.1 
11078 86 
DS 0014 21 
R 03 98 
11295 39 
R 04 97 
JO 129 77 
R 02 39 
S 01 29 
DS 0035 20 
6396 NA 
9302 NA 
DC 509 2.77 
2072 NA 
9880 NA 
9018 NA 
9158 NA 
6300 NA 
9092 a NA 
Test concentration: 80 µg/ml 
NA= Not Active 
Samples showing % Growth Inhibition < 50 are considered inactive  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
Drug Control % Inh 
Amph B 100.0 
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A culture of L. donovani was used to run the anti-leishmania primary screening assay. 
The samples were tested at 80µg/ml. Those extracts (Table 5&6) showing 50% growth inhibition 
or better are retested in a secondary assay.  
 
Table 7: ANTILEISHMANIAL SCREENING ASSAYS-SECONDARY DATA 
Sample Name Leishmania donovani 
IC50 (µg/ml) 
Leishmania donovani 
IC90 (µg/ml) 
 
9002 
 
18 
 
36 
9201 > 40 > 40 
DC 656 > 40 > 40 
6239 18 35 
DC 12 > 40 > 40 
9121 a 40 > 40 
DC 401 6.8 28 
9121 b 15 34 
11078 > 40 > 40 
R 03 > 40 > 40 
R 04 > 40 > 40 
JO 129 > 40 > 40 
JO 61 > 40 > 40 
LG 0038 > 40 > 40 
Test at 3 Concentrations: 40, 8, 1.6 g/ml 
 
IC50 and IC90 are the sample concentrations that kill 50% and 90% cells compared to the solvent control 
 
 
 
 
 
Drug control IC50 (µg/ml) IC90 (µg/ml) 
Pentamidine 1.2 6 
Amph B 0.17 0.35 
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3.1.3.  Antimalarial Data 
Shown in Table 8 & 9 is the primary antimalarial assay. The assays are run at a 
concentration of 15.9 µg/ml against only the chloroquine sensitive, D6 clone of P. falciparum. 
Those extracts showing % growth inhibition less than 50 are considered inactive. The extracts 
showing % growth inhibition more than or equal to 50 are confirmed in secondary assay.  
 
Table 8: ANTIMALARIAL ACTIVITY REPORT- PRIMARY DTA 
 % Inhibition 
Sample Name P. falciparum  
(D6 Clone) 
9002 97 
9201 97 
9121 0 
DC 656 6 
6239 2 
6263 0 
DC 12 99 
DC 486 3 
5952 0 
DC 462 0 
DC 299 0 
2123 4 
6075 91 
9298 0 
6360 0 
9121 a 2 
6060 0 
DC 401 2 
9165 0 
1971 0 
DC 1010 6 
6086 4 
DC 653 0 
DC 10 0 
DC 19 0 
NT = Not Tested 
Samples showing % Growth Inhibition < 50 are considered inactive at 15.9 g/ml (extracts) or 1.59 g/ml (pure)  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
 
26 
 
Table 9: ANTIMALARIAL ACTIVITY REPORT- PRIMARY DTA 
 % Inhibition 
Sample Name P. falciparum  
(D6 Clone) 
1850 0 
6141 10 
1894 0 
1907 41 
DC 38 1 
DC 52 4 
9187 1 
9198 15 
9092 a 0 
6396 18 
9302 0 
11321 28 
JO 61 23 
LG 0125A 15 
LG 0011 43 
DC 3043 11 
JO 184 21 
11310 13 
11076 27 
JM 0070 100 
DC 3412 68 
LG 0038 47 
11078 17 
DS 0014 12 
R 03 66 
11295 14 
R 04 49 
JO 129 0 
R 02 0 
S 01 0 
DS 0035 0 
NT = Not Tested 
Samples showing % Growth Inhibition < 50 are considered inactive at 15.9 g/ml (extracts) or 1.59 g/ml (pure)  
Samples showing % Growth Inhibition > 50 in any organisms are confirmed in secondary assay 
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Shown in Table 10 is the secondary antimalarial assays run at six test concentrations, 
(47600, 15820, 5290, 1760, 560, 195 ng/ml) against both the chloroquine sensitive (D6) and 
chloroquine resistant (W2) clones of P. falciparum. Cytotoxicity testing is also carried out on 
VERO cells (monkey kidney fibroblasts) by Natural Red assay. The extracts which had IC50 
values lower than the lowest test concentration were subjected to further testing. 
 
 
Table 10: ANTIMALARIAL ACTIVITY REPORT- SECONDARY DTA 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity(Vero) 
Sample  IC50 (ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9002 8000 2.5 6000 3.3 20000 
9201 < 195 >244.1 < 195 >244.1 NC 
DC 12 6200 2.9 4700 3.8 18000 
6075 7800 3.5 5800 4.7 27000 
JM 0070 < 195 >244.1 < 195 >244.1 NC 
DC 3412 17000 >2.8 11000 >4.3 NC 
R 03 18000 >2.6 13000 >3.7 NC 
 
Screen Codes:                                                                    Selectivity Index (S. I.) = IC50 (Vero Cells) IC50 (P. falciparum) 
NA = Inactive                                                         Test @ 6 Concentrations:  47600, 15820, 5290, 1760, 560, 195 ng/ml 
NC = No Cytotoxicity 
NT = Not Tested 
 
 
 
 
 
 
 
 
 
Drug Control D6  IC50(ng/ml) W2  IC50(ng/ml) 
Chloroquine 16.0 110 
Artemisinin 5.0 9.5 
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Table 11: ANTIMALARIAL ACTIVITY REPORT- SECONDARY DATA 
 P. falciparum (D6 Clone) P. falciparum (W2 Clone) Cytotoxicity(Vero) 
Sample Name IC50(ng/ml) S. I. IC50 (ng/ml) S. I. IC50 (ng/ml) 
9201 110 >432.7 84 >566.7 NC 
JM 0070 95 >501 67 >710.4 NC 
 
Screen Codes:                                                                           Selectivity Index (S. I.) = IC50 (Vero Cells) IC50 (P. falciparum) 
NA = Inactive                                                                           Test @ 6 Concentrations:  4760, 1587, 529, 176, 56, 19.5 ng/ml 
NC = No Cytotoxicity 
NT = Not Tested 
 
 
 
 
 
3.2.  Compounds isolated from DC401 
DC401 was inoculated onto potato dextrose agar at room temperature (~25-30) for two 
weeks with daily growth monitoring, followed by inoculation onto potato dextrose broth with 
shaking at 160 rpm for 14 days at 30
o
C. After 14
th
 day, the cultures were first filtered through 
sterile cotton using vacuum filtration; activated Dianion HP-20 was added to each flask and was 
returned to the shakers for another day. HP-20 was collected and washed with methanol then 
acetone. Methanol and acetone were combined and evaporated to dryness using a Büchi 
Rotavapor R-200. After evaporating all organic solvent, the remaining residue contained some 
portion of water; liquid- liquid extraction was carried out using, hexane then dichlormethane then 
ethyl acetate. Each organic solvent was dried separately 
 
 
Drug Control D6  IC50(ng/ml) W2  IC50(ng/ml) 
Chloroquine 16.0 110 
Artemisinin 5.0 9.5 
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Figure 8: Structure of compound 1 
 
Altertoxin I ( Compound 1); 3,6a,7,10-tetrahydroxy-4,9-dioxo-4,5,6,6a,6b,7,8,9-
octahydroperylene; was isolated from the DCM extract as reddish brown powder. It displayed 
UV absorbances at λmax (MeOH) 215.0, 257.0, 286.1 and 355.0 nm. Negative ESI-MS showed 
molecular ion peaks at m/z 351.0989 [M-H]
-
 (base peak), 333.0865 [M-H2O]
-
, and 315.0759 [M-
2H2O-H]
-
, indicating a molecular weight of 352 g/mol. The 
13
C NMR spectrum (see Table 12) 
contained signals of twenty carbon atoms, which together with 
1
H, 
13
C NMR and mass spectra 
indicated a molecular formula of C20H16O6. The 
1
H resonances were assigned to two AX spin 
systems of ortho-coupled aromatic protons, one appearing at δH 7.79 and 7.04 (H-1 and H-2, 
respectively), and the other one at δH 6.98 and 7.78 (H-11 and H-12, respectively), and two 
chelated phenolic hydroxyl groups (δH 12.30 and 12.67). In addition, C(5)H2-C(6)H2 and C(8)H2-
C(7)HOH-C(6b)H fragments were observed and assembled on basis of the COSY spectrum (see 
Table 12). The aromatic 
13
C resonances were attributed to two tetra-substituted aromatic rings 
and two carbonyl carbon atoms in two six membered rings, while the remaining signals were 
assigned to three methylene and two methine sp
3 
hybridized carbons, one of which is oxygen-
bearing. The chelated phenolic hydroxyl groups were located at C-3 and C-10 on basis of the 
observed HMBC correlations of H-1 and H-2 to C-3 as well as those of H-11 and H-12 to C-10 
(see Table 12). Consequently, the carbonyl groups were located at C-4 and C-9. Furthermore, 
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HMBC correlations were observed for H-2 to C-3a and C-12b, H-1 to C-3 and C-3b, CH2-6 to C-
4, C-3b, and C-6a besides CH2-5 to C-4 and C-6a, thereby establishing the structure of the half 
part of the molecule. The other part exhibited similar HMBC correlations for the aromatic 
portion, in addition to the correlations observed for H-11 to C-9a, CH2-8 to C-9a and C-9 as well 
as H-6b to C-12a and C-9a. The attachment of both parts of the molecule was deduced from 
HMBC correlations of H-1 to C-12a, H-12 to C-12b along with those of H-6b to C-6 and C-3b 
suggesting the structure of altertoxin I with the phenyl rings being conjugated. The structure was 
further confirmed by comparing 
1
H, 
13
C NMR, and mass spectral data with published data for 
altertoxin I which was previously reported from several  Alternaria species[75-77].  
Table 12: 
1
H, 
13
C NMR, COSY, and HMBC data of compound 1 at 500 (
1
H) and 125 MHz (
13
C) 
in CDCl3 
Compound 1 Altertoxin I[75]  
No.r. δH (J in Hz) δc , mult COSY HMBC δH (J in Hz) δc , mult 
1 1H, 7.79, d (8.8) 132.8, 
CH 
2 C-12a, C-3, C-3B 1H, 7.87, d (8.8) 132.7, CH 
2 1H, 7.04, d (8.8) 119.7, 
CH 
1 C-12b, C-3B 1H, 7.01, d (8.8) 119.5, CH 
 3 - 162.4, qC - - - 162.3, qC 
3a - 113.9, qC - - - 116.9, qC 
3b - 135.8, qC - - - 135.5, qC 
4 - 205.3, qC - - - 205.0, qC 
5 1H, 2.6615, td (17.,3.5)  
 1H, 3.1397, m 
34.1, CH2 6 C-3a, C-6a, 
C-6, C-4 
1H, 2.65, td (15,3)   
1H, 3.17, m 
34.0, CH2 
6 1H,  2.38, dt (14.45, 
3.9);  
1H,  2.9797, m 
34.7, CH2 5 C-6b, C-4,  
C-3b,  
C-5 
1H,  2.43, dt (13, 3);  
1H,  3.17, m 
34.5, CH2 
6a - 69.4, qC - - - 69.2, qC 
6b 1H, 3.0329, d  (8.45) 52, CH 7 C-9a, C-7 1H, 3.09, d  (9) 51.9, CH 
7 1H, 4.7160,ddd(12, 8,  
5) 
66.2, CH 6b, 8 C-6a, C-6b 1H,4.78, ddd (12, 9,  
5) 
66.1, CH 
8 1H, 2.884, dd (12, 16);  
1H, 3.076, dd (4.75, 16) 
47.9, CH2 7 C-9, C-9a,  
C-6b, C-7 
1H, 2.94, dd (12, 16);  
1H, 3.07, dd (5, 16) 
47.7, CH2 
9 - 202.5, qC - - - 202.0, qC 
9a - 117.1, qC - - - 117.4, qC 
9b - 139.3, qC - - - 139.1, qC 
10 - 162.1, qC - - - 162.0, qC 
11 1H, 6.9807, d (8.8) 117.1, 
CH 
12 C-9b, C-12a, C-
10 
1H, 6.92, d (8.8) 117.5, CH 
12 1H, 7.7883, d (8.8) 132.7, 
CH 
11 C-12b, C-10, C-
9b 
1H, 7.82 , d (8.8) 132.4, CH 
12a - 124, qC - - - 124.1, qC 
12b - 123, qC - - - 122.7, qC 
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Figure 9: Structure of compound 2 
     
Compound 2, 6-methoxy-3,6a,7,10-tetrahydroxy-4,9-dioxo-4,5,6,6a,6b,7,8,9-
octahydroperylene, was isolated from the DCM extract as reddish brown powder. It displayed 
UV absorbencies at λmax (MeOH) 207.9, 217.1, 259.0, and 290.0 nm. Negative ESI-MS showed 
molecular ion peaks at m/z 381.0989 [M-H]
-
 (base peak), 363.0865 [M-H2O]
-
, and 315.0759 [M-
2H2O-H]
-
, indicating a molecular weight of 382 g/mol. The 
13
C NMR spectrum (see Table 13) 
contained signals of twenty one carbon atoms, which together with 
1
H, 
13
C NMR and mass 
spectra indicated a molecular formula of C21H18O7. The 
1
H resonances were assigned to two AX 
spin systems of ortho-coupled aromatic protons, one appearing at δH 7.80 and 7.05 (H-1 and H-2, 
respectively), and the other one at δH 6.98 and 7.79 (H-11 and H-12, respectively), and to two 
chelated phenolic hydroxyl groups (δH 12.40 and 12.42). In addition, C(5)H2-C(6)HOCH3 and 
C(8)H2-C(7)HOH-C(6b)H fragments were observed and assembled on basis of the COSY 
spectrum (see Table 13). The aromatic 
13
C resonances were attributed to two tetra-substituted 
aromatic rings, two carbonyl carbon atoms in two six membered rings, and one methoxy group, 
while the remaining signals were assigned to two methylene and three methine sp
3 
hybridized 
carbons, two of which are oxygen-bearing. The chelated phenolic hydroxyl groups were located 
at C-3 and C-10 on basis of the observed HMBC correlations of H-1 and H-2 to C-3 as well as 
those of H-11 and H-12 to C-10 (see Table 13). Consequently, the carbonyl groups were located 
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at C-4 and C-9. Furthermore, HMBC correlations were observed for H-1` to C-6 indicating the 
methoxy group is attached to C-6; H-2 to C-3a and C-12b, H-1 to C-3 and C-3b, CH-6 to C-4, C-
3b, and C-6a besides CH2-5 to C-4 and C-6a, thereby establishing the structure of the northern 
part of the molecule. The southern part exhibited similar HMBC correlations for the aromatic 
portion, in addition to the correlations observed for H-11 to C-9a, CH2-8 to C-9a and C-9 as well 
as H-6b to C-12a and C-9a. The attachment of both parts of the molecule was deduced from 
HMBC correlations of H-1 to C-12a, H-12 to C-12b along with those of H-6b to C-6 and C-3b 
suggesting the structure of compound 2 with the phenyl rings being conjugated. 
 
 
Table 13: 
1
H, 
13
C NMR, COSY, and HMBC data of compound 2 at 500 (
1
H) and 125 MHz (
13
C) 
in CDCl3 
   
No. δH (J in Hz) δc, mult COSY HMBC 
1 1H, 7.80, d (8.8) 132.9, CH 2 C-12a, C-3, C-3B 
2 1H, 7.05, d (8.8 120.1, CH 1 C-12b, C-3B 
3 - 162, qC - - 
3a - 114.3, qC - - 
3b - 136.8, qC - - 
4 - 202.8, qC - - 
5 
1H, 3.3569, dd (1.9, 17.2);  
1H, 3.1335, dd (10, 16) 
37.2, CH2 6 C-3a, C-6a, C-6, C-4 
6 1H, 4.6405, m 79.1, CH 5 C-6b, C-4, C-3b, C-5 
6a - 71.4, qC - - 
6b 1H, 3.5239, d (9.5) 48.2, CH 7 C-9a, C-7, 
7 1H, 4.6405, m 66.1, CH 6b, 8 C-6a, C-6b 
8 
1H, 2.8602, dd (12.2, 16.05); 
1H, 3.1310, dd (16.05, 1.25) 
48.1, CH2 7 C-9, C-9a, C-6b, C-7 
9 - 203, qC - - 
9a - 117.7, qC - - 
9b - 136, qC - - 
10 - 162.6, qC - - 
11 1H, 6.9871, d (8.8) 117.9, CH 12 C-9b, C-12a, C-10 
12 1H, 7.7965, d (8.8) 132.8, CH 11 C-12b, C-10, C-9b 
12a - 124, qC - - 
12b - 124.2, qC - - 
1` 3H, 3.4086, s 56, CH3 - C-6 
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Figure 10: Structure of compound 3 
 
Compound 3 was isolated from the DCM extract as yellow powder. It displayed UV 
absorbances at λmax (MeOH) 215.0, 256.0, 287.0, and 363.0 nm.  Negative ESI-MS showed 
molecular ion peaks at m/z 349.0891 [M-H]
-
 (base peak) and 331.0759 [M-H2O]
-
, indicating a 
molecular weight of 350 g/mol. The 
13
C NMR spectrum (see Table 14) contained signals of 
twenty carbon atoms, which together with 
1
H, 
13
C NMR and mass spectra indicated a molecular 
formula of C20H14O6. The structure of 3 was determined by comparison of its spectral properties 
with those of compound 1. In the 
1
H spectrum, no four methylene protons were observed and 
instead singals due to two olefinic protons newly appeared at δH 6.35 and 7.76 and were adjacent 
to each other. Therefore, compound 3 was a dehydro form of compound 1. The 
13
C resonances 
spectrum also supported the above conclusion.   
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Table 14: 
1
H, 
13
C NMR, COSY, and HMBC data of compound 3 at 500 (
1
H) and 125 MHz (
13
C) 
in CDCl3 
No. δH (J in Hz) δc, mult COSY HMBC 
1 1H, 7.78, d (8.8) 132, CH 2 C-3, C-12a 
2 1H, 7.04, d (8.8) 119.3, CH 1 C-3a, C-12b 
3 - 161.7, qC - - 
3a - 113.1, qC - - 
3b - 138.8, qC - - 
4 - 190.2, qC - - 
5 1H, 6.3567, s (10.35) 126.8, CH 6 C-6a 
6 1H, 7.7680, s (10.35) 150.4, CH 5 C-4, C-3b 
6a - 67.3, qC - - 
6b 1H, 3.18, d (9.7) 51.8, CH 7 C-7, C-9b 
7 1H, 4.75, m 66, CH 6b, 8 - 
8 
1H, 2,82, dd (12.4, 15.8); 1H, 3.11, 
dd (4.65, 15.8) 
      48, CH2 
 
7 C-6b, C-7, C-9 
9 - 202.2, qC  - 
9a - 117.3, qC  - 
9b - 135.5, qC  - 
10 - 162.7, qC  - 
11 1H, 7.00, d (8.8) 117.28, CH 12 C-9a, C-12a 
12 1H, 7.88, d (8.8) 132.61, CH 11 C-12b, C-10, C-9b 
12a - 125.3, qC - - 
12b - 124.6, qC - - 
 
 
Figure 11: Structure of compound 4 
 
Compound 4 was isolated from the DCM extract as yellow powder. It displayed UV 
absorbances at λmax (MeOH) 217.1, 258.0, and 290.0 nm.  Negative ESI-MS showed molecular 
ion peaks at m/z 351.1063 [M-H]
-
 (base peak) and 333.0849 [M-H2O]
-
, indicating a molecular 
weight of 352 g/mol. The 
13
C NMR spectrum (see Table 15) contained signals of twenty carbon 
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atoms, which together with 
1
H, 
13
C NMR and mass spectra indicated a molecular formula of 
C20H16O6. The structure of 4 was determined by comparison of its spectral properties with those 
of compound 1. In the 
13
C spectrum, one of methylene carbons became a methine carbon with 
oxygen bearing and one of carbonyl carbon became methine with oxygen bearing. The 
1
H 
resonances spectrum also supported the above conclusion.   
 
Table 15: 
1
H,
13
C NMR, COSY, and HMBC data of compound 4 at 500 (
1
H) and 125 MHz (
13
C) 
in CD3OD 
No. δH (J in Hz) δc, mult COSY HMBC 
1  1H, 8.0363, d (8.85) 134.1, CH 2 C-3, C-3b, C-12a 
2  1H, 7.0075, d  (8.85) 119.7, CH 1 C-3a, C-12b. C-3 
3 - 163.1, qC - - 
3a - 115.1, qC - - 
3b - 140.9, qC - - 
4 - 206.8, qC - - 
5 1H, 2.81, m; 1H, 3.16, m 34.38, CH2 6 C-6a, 
6 1H, 2.39, dt (14, 4);1H, 2.73, m 34.49, CH2 5 C-4, C-3b 
6a  69.2, qC   
6b 1H, 3.49, s 46.17, CH 7 C-9b, C-7, C-8, C-9b 
7 1H, 3.86, d (3.7) 51.2, CH 6b, 8 C-6a, C-9b 
8 1H, 3.55, d (3.35) 56.87, CH 7,9 C-9a 
9 1H, 5.25, s 62.0, CH 8 C-7, C-8, C-9a, C-10 
9a - 123.3, qC - - 
9b - 128.4, qC - - 
10 - 157.9, qC - - 
11  1H, 6.8521,d (8.45) 115.3, CH 12 C-9a, C-12a, C-10 
12  1H, 7.5932,d (8.45) 125.6, CH 11 C-9b, C10, C-12b 
12a - 125.8, qC - - 
12b - 125.6, qC - - 
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Figure 12: Structure of compound 5 
 
Compound 5 was isolated from the DCM extract as yellow powder. It displayed UV 
absorbances at λmax (MeOH) 217.1, 258.1, and 290.0 nm.  Positive ESI-MS showed molecular 
ion peaks at m/z 383.1101 [M+H]
+
 (base peak) and 787.1942 [2M+Na]
+
  and negative ESI-MS 
showed molecular ion peaks at m/z 381.1275 [M-H]
-
 (base peak) and 763.2489 [2M-H]
-
, 
indicating a molecular weight of 382 g/mol. The 
13
C NMR spectrum (see Table 16) contained 
signals of twenty one carbon atoms, which together with 
1
H NMR and mass spectra indicated a 
molecular formula of C21H18O7. The structure of 5 was determined by comparison of its spectral 
properties with those of compound 4. In the 
13
C spectrum, one of methylene carbons became a 
methine carbon with oxygen bearing which was C-6 and there is a methoxy group δc at 57.2 
which was attached to C-6. The 
1
H resonances spectrum also supported the above conclusion.   
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Table 16: 
1
H, 
13
C NMR, COSY, and HMBC data of compound 5 at 500 (
1
H) and 125 MHz (
13
C) 
in CD3OD 
No. δH (J in Hz) δc, mult COSY HMBC 
1 1H, 8.012, d (8.9) 134.0, CH 2 C-3, C-3b, C-12a 
2 1H, 7.00, d (8.9) 119.6, CH 1 C-12b, C-3a 
3 - 162.3, qC - - 
3a - 115.4, qC - - 
3b - 138.6, qC - - 
4 - 204.7, qC - - 
5 
1H, 3.155, dd (2.7, 17.6); 
1H, 3.3499 m 
37.8, CH2 
6 C-3a, C-6a 
6 H, 4.318, s 80.6, CH 5 C-4, C-3b, C-1`, C-6b 
6a - 71.6, qC - - 
6b 1H, 3.618, s 41.3, CH 7 C-6, C-8, C-3b 
7 1H, 3.739, (3.35) 51.0, CH 6b, 8 C-6a, C-9, C-9b 
8 1H, 3.518, q 56.8, CH 9, 7 C-6b, C-9a 
9 1H, 5.263, s 62.1, CH 8 C-10, C-7, C-9a 
9a - 123.5, qC - - 
9b - 128.8, qC - - 
10 - 157.9, qC - - 
11 1H, 6.832, d, (8.4) 115.1, CH 12 C-9a, C-12a 
12 1H, 7.572, d (8.4) 125.6, CH 11 C-10, C-9b, C-12b 
12a - 125.4, qC - - 
12b - 126.9, qC - - 
1` 3H, 3.48, s 57.2, CH3 - C-6 
 
 
 
Figure 13: Structure of compound 6 
 
Compound 6 (7-chloroscytalone) was isolated from ethyl acetate fraction. It displayed 
UV absorbances at λmax (MeOH) 226.0 and 286.1 nm.  Positive ESI-MS showed molecular ion 
peaks at m/z 229.0299 [M+H]
+
 (base peak) and negative ESI-MS showed molecular ion peaks at 
m/z 227.0447 [M-H]
-
 (base peak), indicating a molecular weight of 228 g/mol. Also, ESI-MS 
showed there is a halogen atom. The 
13
C NMR spectrum (see Table 17) contained signals of ten 
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carbon atoms, which together with 
1
H NMR and mass spectra indicated a molecular formula of 
C10H9ClO4. The 
1
H resonances were assigned to two AB spin systems of methylene, one 
appearing at δH 2.65 and 2.88 (H-2a and H-2b, respectively) and the other one at δH 2.84 and 3.08 
(H-4a and H-4b, respectively) and one singlet aromatic proton at δH 6.36,. In addition, C(2)H2-
C(3)HOH-C(4)H2 fragment was observed and assembled on basis of the COSY spectrum (see 
Table 17).  
 
Table 17: 
1
H, 
13
C NMR, COSY, and HMBC data of compound 6 at 500 (
1
H) and 125 MHz (
13
C) 
in CD3OD 
No. δH (J in Hz) δc, mult COSY HMBC 
1 - 202.9, qC - - 
2 
1H, 2.657, dd (7.5,17) 
1H, 2.8882, dd (3.5, 13.9) 
47.2, CH2 3 C-1, C-4 
3 1H, 4.284, m 66.9, CH 2, 4 C-1, C-4a 
4 
1H, 3.0887, dd(3.45,16.15) 
1H, 2.848, dd (7.2, 16.2) 
38.8, CH2 3 
C-2, C-1, C-4a, 
 C-5, C-8a 
4a - 143.3, qC - - 
5 1H, 6.3696, s 109.2, CH - C-4, C-7, C-8a 
6 - 
- 
161.7, qC - - 
7 - 106.7, qC - - 
8 - 161.9, qC - - 
8a - 112, qC - - 
 
 
3.3.  Stereochemistry 
Compound 1 possesses three stereogenic centers, C-6a, C-6b, and C-7. The specific 
optical rotation [α] of compound 1, [α] 21
D  
is +540 (c= 0.05 acetone); the experimental Circular 
dichroism (CD) is shown in Figure 14. The most intense features in the CD spectra are the 
negative CD at 223 nm and the positive CD at 240 nm and at 270 nm. The configurations at C-
6a, C-6b, and C-7 are currently being elucidated by theoretical CD calculations. 
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Figure 14: The CD spectra of compound 1 
 
Compound 2 possesses four stereogenic centers, C-6, C-6a, C-6b, and C-7. The specific 
optical rotation [α] of compound 2, [α] 21
D  
is +168 (c= 0.05 acetone). The experimental CD is 
shown in Figure 15. The most intense features in the CD spectra are the positive CD at 230 nm. 
The configurations at C-6, C-6a, C-6b, and C-7 are currently being elucidated by theoretical CD 
calculations. 
  
 
Figure 15: The CD spectra of compound 2 
 
Compound 3 possesses three stereogenic centers, C-6a, C-6b, and C-7. The specific 
optical rotation [α] of compound 3, [α] 21
D  
is +516 (c= 0.05, acetone). The experimental CD is 
shown in Figure 16. The most intense features in the CD spectra are the positive CD at 240, 270, 
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310, and 410 nm and the negative CD at 220 and 350 nm. The configurations at C-6a, C-6b, and 
C-7 are currently being elucidated by theoretical CD calculations. 
 
Figure 16: The CD spectra of compound 3 
 
Compound 4 possesses five stereogenic centers, C-6a, C-6b, C-7, C-8 and C-9. The 
specific optical rotation [α] of compound 4, [α] 21
D
 is +88 (c= 0.05 acetone). The experimental CD 
is shown in Figure 17. The most intense features in the CD spectra are the negative CD at 210 
nm and the positive CD at 230 nm. The configurations at C-6a, C-6b, C-7, C-8, and C-9 are 
currently being elucidated by theoretical CD calculations. 
 
 
Figure 17: The CD spectra of compound 4 
 
Compound 5 possesses six stereogenic centers, C-6, C-6a, C-6b, C-7, C-8, and C-9. The 
specific optical rotation [α] of compound 5, [α] 21
D
 is +160 (c= 0.05 acetone). The experimental 
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CD is shown in Figure 18. The most intense features in the CD spectra are the positive CD at 230 
nm and the negative CD at 210 and 260 nm. The configurations at C-6, C-6a, C-6b, C-7, C-8, 
and C-9 are currently being elucidated by theoretical CD calculations. 
  
 
Figure 18: The CD spectra of compound 5 
 
Compound 6 possesses one stereogenic center, C-3. The specific optical rotation [α] of 
compound 6, [α] 21
D  
is -84 (c= 0.05 acetone). The experimental CD is shown in Figure 19. The 
most intense features in the CD spectra are the negative CD at 210 nm and the positive CD at 
230 nm. The configuration at C-3 is currently being elucidated by theoretical CD calculations. 
 
 
Figure 19: The CD spectra of compound 6 
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3.4. Biological Activity 
Compound 2 showed antileishmanial activity against Leishmania donovani with IC50 = 
3.14 µg/ml and IC90 = 14.69 µg/ml. Compound 3 showed antileishmanial activity against 
Leishmania donovani with IC50 = 1.4 µg/ml and IC90 = 5.754 µg/ml and antimalarial activity 
against both the chloroquine sensitive (D6) and chloroquine resistant (W2) clones of P. 
falciparum with IC50 = 3.164 µg/ml and 2.459 µg/ml respectively and cytotoxicity activity 
against mammalian kidney fibroblasts (VERO cells) with IC50 = 4.414 µg/ml. Other compounds 
did not show any activity. 
 
3.5. Biosynthesis of reduced perylenequinones 
Compounds 1, 2, 3, 4, and 5 are examples of reduced perylenequinones so far identified 
in fungi. The biosynthesis of these compounds occurs most probably via oxidative coupling of 
two molecules of a tetralone derivative synthesized from a pentaketide derivative[76] by so-
called head to head coupling, followed by reduction and hydroxylation in different positions. The 
proposed biosynthetic pathway was confirmed by incorporation experiment of 
13
C-labelled 
sodium acetate and may be depicted as shown in Figure 20.  
 
Figure 20: Proposed biosynthetic pathway of reduced perylenequinone
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4. EXPERIMENAL METHODS  
 
4.1. General Experimental Procedures 
Optical rotations were recorded using a Rudolph Research Analytical Autopol V 
polarimeter. UV was obtained using a Perkin-Elmer Lambda 3B UV/visspectrophotometer. 
1
H 
and 
13
C spectra were recorded on Bruker model AMX 500 NMR spectrometers and Bruker 
model AMX 400 NMR spectrometers with standard plus sequences, operating at 500 MHz and 
400MHz in 
1
H and 125 MHz and 100 MHz in
 13
C respectively. The chemical shift values were 
reported in parts per million units (ppm) from trimethylsilane (TMS) using known NMR solvent 
chemical shifts. Couple constants were recorded in Hertz (Hz). Standard pulse sequences were 
used for COSY, DEPT, HMQC, and HMBC. A Micromass Q-Tof Micro mass spectrometer with 
a lock spray source was used to measure high resolution mass spectra. The experimental CD data 
was measured at 5 
o
C by Olis CD Spectrophotometer. Sephadex LH-20 (Mitsubishi Kagaku, 
Tokyo, Japan) and silica gel (70-230 mesh, Merck) were used for column chromatography. 
Fractions from column chromatography were monitored using TLC, silica gel F254. Preparative 
TLC was carried out on silica gel 60 PF254+60366 plates (20 x 20 cm, 1 mm thick). 
Visualization of the TLC plates was achieved with a UV lamp (λ=254 and 365 nm) and p-
anisaldehyde/acid spray reagent (MeOH: acetic acid: anisaldehyde: sulfuric acid, 85:9:1:5).  
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4.2. Chemicals 
All chemicals used were from Sigma-Aldrich (Poole, U.K.). All HPLC solvents were 
HPLC grades and were purchased from Sigma-Aldrich 
 
4.3. Antimicrobial assay 
All organisms used for the antimicrobial evaluations of the metabolites from endophytic 
fungi were obtained from the American Type Culture Collection (Manassas, VA) and include the 
fungi Candida albicans ATCC 90028, Candida glabrata ATCC 90030, Candida krusei ATCC 
6258, Cryptococcus neoformans ATCC 90133, and Aspergillus fumigates ATCC 204305 and the 
bacteria Staphyococcus aureus ATCC 29213, methicillin-resistant S. aureus ATCC 33591 
(MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853, and 
Mycobacterium intracellulare ATCC 23068. Susceptibility testing is carried out using a 
modified version of National Committee for Clinical Laboratory Standards (NCCLS) methods. 
M. intracellulare was tested using a modified method of Franzblau et al[78]. Samples tested 
were serially-diluted in 20% DMSO/saline and transferred in duplicate to 96 well microplates. 
The microbial subcultures were prepared and diluted in broth to reach the desired colony forming 
unites (CFU) per milliliter. The samples were added to the microbial inocula to achieve a final 
volume of 200µl and test concentration of 50µg/ml for crude extracts and 20µg/ml for pure 
compounds. Controls, growth (saline only), solvent, and blank (media only), were included on 
each test plate. Amphotericin B (ICN Biomedicals, Ohio) for fungi and ciprofloxacin (ICN 
Biomedicals, Ohio) for bacteria were used as positive controls in each assay. Plates are read 
using either optical density at 630 nm using the EL-340 Biokinetics Reader (Bio-Tek 
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Instruments, Vermont) or fluorescence at 544ex/590em (M. intracellulare, A. fumigates) using 
the Polarstar Galaxy Plate Reader (BMG LabTechnologies, Germany). Percent of growth was 
calculated and plotted versus the test concentration to produce the IC50 which is the 
concentration of the sample that inhibits 50% growth of the organism. The minimum inhibitory 
concentration (MIC) is the lowest test concentration that does not allow any detectable growth. It 
is determined only for pure compounds. 
 
4.4. Antimalarial Assay 
Antimalarial activity was determined in vitro against chloroquine sensitive (D6, Sierra 
Leone) and resistant (W2, Indo China) strains of Plasmodium falciparum. The assay is based on 
evaluation of the effect of the test compounds on the growth of cultures of Plasmodium 
falciparum and determined by the assay of plasmodial lactate dehydrogenase (LDH) activity. 
The test compounds were dissolved in DMSO (2mg/ml). A 200 µl suspension of Plasmodium 
falciparum culture (2% parasitemia and 2% hematocrit in RPMI 1640 medium supplemented 
with 10% human serum and 60 µg/mL amikacin) was added to the wells of a 96-well plate 
containing 10 µL of serially diluted samples. The plates were put in a humidified chamber and 
flushed with a gas mixture of 90% N2, 5% O2, and 5% CO2 and incubated at 37 
o
C for 72 hours. 
Plasmodial LDH activity was determined by using Malstat™ reagent (Flow Inc., Portland, OR). 
Briefly, 100 µL of the Malstat reagent was added to 20 µL of the incubation mixture and 
incubated for 30 min. After that, 20 µL of a 1:1 mixture of NBT/PES (Sigma, St. Louis, MO) 
was added and the plate was further incubated for 1 h in dark. The reaction was stopped by 
adding 100 µL of a 5% acetic acid solution. The plate was measured at 650 nm using the EL-340 
Biokinetics Reader (Bio-Tek Instruments, Vermont). The primary screening of the crude 
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extracts/ fractions was run at a single concentration 15 µg/ml only on chloroquine sensitive (D6) 
strain of P. falciparum. The extracts showing > 50% inhibition in the growth of the parasite were 
tested at three concentrations in the secondary screening. Chloroquine and artemisinin were 
included in each assay as the positive controls while DMSO (0.25%) was used as the negative 
control. IC50 values were obtained from the dose-response curves generated by plotting percent 
growth versus concentrations of tested compounds.  
 
4.5. Leishmania assay 
The antileishmanial activity of the crude extracts/fractions/ or pure compounds was 
measured in vitro against a culture of Leishmania donovani promastigotes. Compounds tested 
were added to the Leishmania promastigotes or the axenic amastigotes cultures containing 2 x 
10
6
 cells/ml. The plates were incubated at 26 
o
C for 72 hours and the growth of Leishmania 
promastigotes/axenic amastigotes was determined using AlamarBlue® Assay. Pentamidine and 
amphotericin B were used as the positive controls. IC50 and IC90 values were computed from the 
dose-response curves.  
 
4.6. In Vitro Cytotoxicity Assay 
The Cytotoxicity of compounds was determined against mammalian kidney fibroblasts 
(VERO cells) obtained from American Type Culture Collection (ATCC, Rockville, MD). The 
assay was carried out in 96-well tissue culture-treated microplates. Cells were seeded in the wells 
of a 96-well plate at a density of 25,000 cells/well and incubated for 24 h. Samples were added at 
different concentrations to the wells and plates were again incubated for 48 h. The number of 
viable cells was measured using Neutral Red according to a modification of the procedure of 
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Borenfreund and Babich. IC50 values were measured from dose response curves. Doxorubicin 
was chosen as a positive control and DMSO was used as a negative control.   
 
4.7. Cultivation 
Received fungi from our colleague were grown on Potato Dextrose Agar (PDA) plates at 
a room temperature ~ 28 
o
C for 14 days with daily growth monitoring. Plates were kept in 
refrigerator and used when needed. 
 For small scale extractions, the fungi were grown on small scale using Potato Dextrose 
Broth (PDB, Sigma-Aldrich Chemie). PDB media was prepared by dissolving 24 g of PDB in 1L 
distilled water and the autoclaved. Fifty ml of PDB was placed in 125ml conical flasks and 
incubated with small pieces of actively growing mycelium. The cultures were incubated at 30 
o
C 
under orbital agitation (160rpm) for 14 days. After incubation, the contents of the flasks were 
filtered through sterile cotton using vacuum filtration and then the filtrates were extracted 
exhaustively with ethyl acetate. The organic phase was vacuum concentrated to obtain the 
extracts. The extracts were sent to biological assays.  
For large scale extractions, 1L of PDB placed in 2800ml Fernbach flasks were autoclaved 
and incubated with small pieces of actively growing mycelium. The cultures were incubated at 
30 
o
C under orbital agitation (160rpm) for 14 days. After incubation, the contents of the flasks 
were filtered through sterile cotton using vacuum filtration. After filtration 100g activated ion 
exchange resin (Diaion-HP20) was added to each 1L of filtrates. It was returned to shakers and 
left overnight. After that it was filtrated and HP20 was washed with water, methanol, and then 
acetone. Methanol and acetone were combined and dried under vacuum. The residue was 
dissolved in water and extracted with hexane, dichloromethane, and ethyl acetate respectively. 
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4.8. Isolation 
Compounds 1-4 were isolated from DCM fraction. DCM fraction was fractioned using a 
solid phase extraction (SPE) cartridge C-18 under vacuum. Four fractions were obtained. 
Fraction 2 was subjected to open column chromatography using Chloroform (CHCl3)-Methanol 
(MeOH) (silica gel 60, 70-230 mesh, Merck), which yielded several fractions. Fraction 2 and 3 
were combined and chromatographed using preparative TLC with CHCl3-MeOH (98:2) five 
runs, affording compounds 1-4. The HPLC method for fraction 4 was developed on analytical 
HPLC [High Performance Liquid Chromatography; Waters Delta Prep 4000 with Waters 2487 
dual λ absorbance detector and Polymer Laboratories Evaporative Light Scattering (PL-ELS 
1000) detector attached] to obtain compound 5 using a Waters
®
 Atlantis
®
 5µ, C18 T3, 250 x 
4.6mm column an isocratic for 5 min 100% water, then a gradient from 100% water to 100% 
MeOH at a flow rate of 1ml/min over a 70 min time span. It was scaled up on preparative HPLC 
using a Waters
®
 Atlantis
®
 5µ, C18 T3, 250 x 19mm column at a flow rate of 17ml/min with the 
same solvent system that was used on analytical. 
 
Figure 21: HPLC chromatogram for Fraction 4 to get compound 5 
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Compound 6 was isolated from the ethyl acetate fraction. The ethyl acetate fraction was 
chromatographed using C-18 SPE cartridge under negative pressure, giving 11 fractions. 
Fractions 1, 2, and 3 were combined and purified by HPLC to obtain compound 6 using a 
Waters
®
 Atlantis
®
 5µ, C18 T3, 250 x 4.6mm column an isocratic for 5 min 100% water + 0.1% 
formic acid (FA), then a gradient from 100% water + 0.1% FA to 100% MeCN + 0.1% FA at a 
flow rate of 1.5ml/min over another 75 min time. It was scaled up on preparative HPLC using a 
Waters
®
 Atlantis
®
 5µ, C18 T3, 250 x 19mm column at a flow rate of 25.5ml/min with the same 
solvent system that was used on analytical HPLC method. 
 
Figure 22: HPLC chromatogram for combined Fraction 1, 2, and 3 to get compound 6 
 
Scale-up calculations 
The scale-up procedure was calculated according the following equation 
F2 = F1 x L2/L1 x (r2/r1)
2
. 
 
F2 = flow rate of column2; F1 = flow rate of column1; L2 = length of 
column2; L1 = length of column1; r2 = radius of column2; r1 = radius of column1
 
Column2 is the preparative HPLC column and Column1 is the Analytical HPLC column 
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PART B- MICROBIAL BIOTRANSFORMATION OF 5, 7, 2`, 4`, 5`-
PENTAHYDROXYFLAVONOL
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1. Introduction  
Biotransformation is defined as the use of biological systems to modify substances that 
are not used for growth[79]. Microbial transformation is one of the reactions under 
biotransformation beside enzymes, plant tissues, and animal cells. Bioconversion is another term 
related to microbial transformation. Biotransformation is also known to comply with the green 
chemistry strategy today. Green Chemistry is a term used for sustainable chemical industrial 
manufacturing processes towards achieving minimal waste production and energy consumption.  
Biosynthesis and biotransformation are expected to play a major role in green chemistry in the 
years to come[80]. 
Biotransformation leads to modify chemical structure and therefore change activity of the 
biotransformed compound, if the activity and structure are only correlated. Microorganisms can 
catalyze a number of reactions which are crucial for maintaining the life functions of the cell 
including growth and reproduction because they have different types of enzymes. More than 
2000 enzymes have been listed till now. Each of them accepts a certain substrate and catalyzes a 
particular reaction which usually represents a certain metabolic pathway. In addition their natural 
substrates many enzymes accept foreign substrates and catalyze unnatural reactions with the 
substrates that were supplied to the medium[81, 82]. Biotransformation reactions can be done 
within growing cultures, previously grown cultures, or purified enzymes. The biotransformed 
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products are isolated from the whole broth or the reaction medium after removing the biomass by 
filtration or centrifugation. Isolated products can be further purified by using chromatographic 
techniques[83].  Biotransformation studies using microbial systems or microbial 
biotransformations have been used as models to study the metabolism of drugs in human systems 
or conversion into relative structures having a better therapeutic index then their parent 
compounds for use as pharmacophores in drug discovery[84, 85].  For example, Otten et al 
(1979) reported microbial transformation of Lapachol into Dehydro-α-lapachone3 which has 
been shown to possess antibacterial and anti-tumor activities whereas Lapachol itself does not 
have any anti-tumor activity[86].  
 
Figure 23: Conversion of Lapachol to Dehydro- α -Lapachone by Curvularia lunata. 
 
Cunninghamella elegans has been used as a model system in understanding the 
metabolism of drugs in animal and human systems. Cunninghamella elegans has been found to 
metabolize Mirtazapine antidepressant drug acting on α2-adrenergic receptors via the same 
metabolic pathways as found in the human systems [87-89].  
Types of chemical reactions carried out by microorganisms include oxidation, reduction, 
hydrolysis, decarboxylation, deamination, amination, phosphorylation, racemization, 
dehydration, demethylation, and condensation. An oxidation reaction is where oxygen is added 
Dehydro- α -Lapachone 
53 
 
to the molecule or when hydrogen is removed while a reduction reaction is where hydrogen is 
added or oxygen is removed. Specific hydrolysis occurs when water is added to a certain linkage 
followed by splitting of the molecule. Decarboxylation reaction is where carbon dioxide is 
eliminated from the molecule whereas deamination reaction occurs when amino groups are 
removed from the molecule. Amination is the reaction of introducing amino group into the 
molecule and phosphorylation is where phosphate esters are added directly to the molecule. 
Racemization can also be resulted where optically active compounds are converted into 
enantiomers. Dehydration and demethylation are reactions eliminating water and methyl group 
respectively[80].  
 
1.1. Advantages of microbial transformation 
Biotransformations have a number of advantages, when compared to the corresponding 
chemical methods.  Many biotransformations are regio-, distereo-, and enantiospecific 
reactions[90] because of that, chiral products can be made from racemic mixtures. Enzymes act 
under mild conditions in the majority of cases; they do not require the protection of preexisting 
functional groups. This minimizes problems of unwanted side-reactions such as decomposition, 
rearrangement, racemization, and isomerization which often happen with chemical methods. 
They are also chemoselective and it is possible to obtain structural transformations at positions 
that are chemically unreactive.  Biosynthetically directed transformations are used to obtain 
biosynthetic information and the design of selective biosynthetic inhibitors. The main feature in 
any biotransformation is the topological relationship between the substrate and the active site of 
the enzyme. Financially, some biotransformations can be cheaper and more direct than their 
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chemical analogs. The transformations proceed under conditions that are normally regarded as 
environmentally friendly[80, 82].  
 
1.2. Model Systems for Drug Metabolism 
Drug metabolism or transformation involves two phases; phase I reactions (oxidation, 
reduction, and hydrolysis reactions) and phase II reactions (Conjugation). Drug metabolism is a 
crucial step in the process of drug action along with adsorption, distribution, and elimination. In 
this step drug biotransformation takes place resulting in the formation of either less toxic and 
highly polar substances or active metabolites. 
  
1.2.1. Animal Model Systems for Drug Metabolism  
Laboratory animals like rats, dogs, guinea pigs, rabbits, and monkeys, are used as models 
for studying of drug metabolism. After administrating the drug to a series of one of these 
animals, their body fluids are collected and examined for the presence and identification of 
metabolites. It is important to get all the metabolites of a drug in needed proportions for further 
pharmacological and toxicological evaluations. The one of the main disadvantages of this model 
is cost of animals. Also, it is impossible to isolate and identify all the metabolites because they 
are present in low concentrations[91].  
 
1.2.2. Microbial Model Systems for Drug Metabolism   
Fungi are playing a remarkable role of catalysis of organic compounds and the 
production of commercially and industrially important compounds because of their ability to 
catalyze novel reactions[91]. They are commonly used in industry for production of fermented 
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beverages, foods, physiologically active substances, solvents, organic acids, polysaccharides, 
antibiotics, and etc. Ascomycota, Saccharomyces, and Schizosaccharomyces are the main fungi 
used in alcoholic beverage fermentations. Rhizopus strains are important in citric acid 
production. Zygomycota, Mucor, and Rhizopus are commonly used in industry. Mucor strains 
make a significant number of important lipases and catalyze the hydroxylation of a wide range of 
chemical compounds. Fungi are specifically important in both industry and research.  
Bacterial transformation involves changes in the structures of organic compounds 
through degradation pathways. That is why many biologically inactive compounds or 
compounds with low activities can be converted into more potent bioactive compounds. For 
example,  Daidzein which has a potent estrogenic activity was converted to Equol. Equol has a 
much stronger estrogenic activity than the parent compound, Daidzein. The conversion of 
Daidzein to Equol was carried out by a mixture of Bacteroides ovatus, Ruminococcus productus, 
and Streptococcus intermedius or Lactobacillus mucosae, Enterococcus faecium, Finegoldia 
magna, and Viellonella sp..   
 
Figure 24: Microbial transformation of Daidzein to Equol 
 
Many of observations on fungi showed that fungi have monooxygenase enzyme system 
confirmed to be mechanistically similar to mammalian hepatic monooxygenases. Many chemical 
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reactions, like hydroxylations, O- and N-dealkylation reactions, can be carried out by microbes 
so microbial transformation systems could mimic most of the Phase I transformations of drugs 
that are observed in mammals.  
 
1.3. Advantages of using microbial systems as models for drug metabolisms 
Keeping of stock cultures of microorganisms is cheaper than the keeping of laboratory 
animals or cell of tissues cultures. In cases where region- and stereo-specificity is involved, the 
models can be useful. Enough amounts of metabolites can be obtained because amounts of 
natural drugs that are used in microbial models are much higher than those used in tissue or 
animal models. Pharmacological and toxicological evaluations for the metabolites can be done 
by scaling up the model to get enough concentrations of the metabolites. New metabolites can be 
isolated with or without new or different activities. The favored metabolic reactions can be 
predicted. In early phases of drug development, it is useful for reducing the demand for animals. 
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2. Results and Discussion 
Three microorganisms, TCC 22752(Absidia glauca), TCC 9628(Mucor ramannianus), 
and TCC 13144 (Beauveria bassiana) were used to identify organisms capable of transforming 
our compound. A standard two-stage fermentation procedure was implemented using potato 
dextrose broth (PDB) with corresponding controls to ensure that new compounds were obtained 
due to enzymatic biotransformation. The substrate was added to a level of 0.5 mg/ml in the 
culture. Detection of metabolites was performed by TLC and visualized using P- anisaldehyde 
spray reagent. Absidia glauca ATCC 22752 was selected for further investigation because it 
metabolized  5, 7, 2`, 4`, 5`-pentahydroxyflavonol and the complexity of its metabolite profile as 
determined by TLC analysis. 
Compound 7: (5, 7, 2`, 4`, 5`-pentahydroxyflavonol) was isolated as yellow powder from 
Limonium gmelinii by Dr. Ross’ group. It was characterized as 5, 7, 2`, 4`, 5`-
pentahydroxyflavonol whose structure was determined on the basis of its MS and homo-and 
heteronuclear 2D NMR spectroscopic data. Compound 7, Mass spectrum (EI, m/z): 318(100) 
[M]
 +, 301 (17), 269 (4), 244 (8), 152 (38), 135 (18), 107 (10), 64 (49); UV (MeOH): λ max 255, 
370 nm, UV (NaOAc): λ max 270, 325, 405 nm (free OH at C-7). The 
1
H spectrum in CDCl3 at 
400 MHz showed: 6.16(1H, d, J = 1.6 Hz, H-6), 6.14 (1H, d, J = 2 Hz, H-8), 7.66 (1H, d, J = 0.8 
Hz, H-5
’
), 7.75(1H, d, J = 1.6, H-2
’
). The 
13
C NMR spectrum in CDCl3 at 100 MHz showed: 
93.4(C-8), 98.3 (C-6), 103.0 (C-10), 111.5 (C-2
`
), 114.1 (C-5
`
), 121.1 (C-1`), 136.1 (C-3)
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140.1 (C-4`), 141.2 (C-3`), 146.1 (C-6`), 146.6 (C-2), 156.6 (C-5), 160.7 (C-9), 164.0 (C-7), 
175.9 (C-4). 
 
2.1. Incubation 
Compound 7 (5, 7, 2`, 4`, 5`-pentahydroxyflavonol) was incubated for 14 days with stage 
II cultures of Absidia glauca ATCC 22752. The medium was extracted thrice with isopropanol: 
ethyl acetate (2:9) and the organic layer was dried over anhydrous sodium sulfate, filtered, and 
evaporated under reduced pressure. The extract was subjected to Sephadex-LH20 column 
chromatography and HPLC with a variety of solvent systems. Two biotransformed metabolites 
were obtained.  
Compound 8: (5, 7, 2`, 5`-tetrahydroxyflavonol-4`- sulfate) was isolated as a yellow 
powder. Its HRESIMS showed an [M+Na] ion peak at m/z 420.985, [M+H] ion peak at m/z 
399.0032, and [M-OSO4H] ion peak at m/z 301.2863, indicating the presence of sulfate in the 
molecule. The UV spectrum of 8 in MeOH showed two peaks at λ max 255 nm (Band I) and 370 
nm (Band II) characteristic for a flavonol skeleton. λ max  MeOH + NaOAc: 275 nm and 385 nm ( 
shift in band I by 20 nm indicates free OH at C-7; bathochromic shift); λ max  MeOH + NaOMe: 
270 nm and 410 nm ( shift with decrease in the intensity in band II by 40 nm indicates that OH at 
C-4` is not free; hypsochromic shift ); 
1
H-NMR in CD3OD at 400 MHz: δ 7.770 (1H, s, H-2`), 
7.668 (1H, s, H-5`), 6.414 (1H, d, J=2 Hz, H-8), 6.173 (1H, d, J=2 Hz, H-6). 
13
C-NMR IN 
CD3OD AT 100 MHz showed: 176.2 (C=O), 164.0 (C-7), 161.1 (C-9), 156.2 (C-5), 147.0 (C-2), 
140.5 (C-4`), 141.7 (C-3`), 136.5 (C-3), 121.5 (C-1`), 146.5 (C-6`), 113.9 (C-5`), 112.1 (C-2`), 
103.4 (C-10), 93.0 (C-8), 97.9 (C-6). The spectral data for compound 8 match favorably with 
5,7,2`,5`-tetrahydroxyflavonol-4`-sulfate. 
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Compound 9: (5, 7, 2`,5`- tetrahydroxyflavonol-8, 4`-disulfate): was isolated as a yellow 
powder. Its HRESIMS showed [M-H]
+ 
ion peak at m/z 492.9161. The UV spectrum of 9 in 
MeOH displayed two peaks at λ max 255 nm (Band I) and 375 nm (Band II) which are 
characteristic for a flavonol skeleton. λ max MeOH + NaOAc: 280 nm and 410 nm (bathochromic 
shift of about 15 nm in band I indicating C-7 hydroxyl is free); λ max MeOH + NaOMe : 330 nm 
(hypsochromic shift of 40 nm in band II indicating C-4 hydroxyl is substituted). 
1
H-NMR 
spectrum in CD3OD at 400 MHz showed: δ 7.970 (1 H, s, H-2`), 7.760 (1 H, s, H-5`), and 6.330 
(1 H, s, H-6); with the disappearance of the proton at C-8. 
13
C-NMR spectrum in CD3OD at 100 
MHz showed: 176.0 (C=O), 168.2 (C-7), 161.0 (C-9), 158.9 (C-5), 147.0 (C-2), 140.0 (C-4`), 
140.3 (C-3`), 136.5 (C-3), 121.9 (C-1`), 145.9 (C-6`), 114.6 (C-5`), 111.9 (C-2`), 103.4 (C-10), 
146.4 (C-8), 98.1 (C-6). The disappearance of H-8 and the chemical shift of C-8 (146.4 ppm) as 
well as the downfield shift of C-7 and C-5 (4.2 and 2.8 ppm respectively) supports sulphate at 
the C-8. The spectral data for compound 3 match agreeably with 5, 7, 2`, 5`- 
tetrahydroxyflavonol-8, 4`-disulfate.  
 
2.2. Plant material 
 Limonium myrianthum was collected in an Almaty region during flowering in August 
2008 and was identified by Dr. Raihan Egeubaeva (Institute of Botany Al-Farabi National 
Khazak University and a specimen was deposited at the same University. 
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2.3. Antimicrobial assay 
The compound 7 displayed significant antifungal activity against Candida glabrata and 
Candida krusei at IC50 4.44 and 9.56 µg/ml, respectively. Microbial transformed compounds did 
not have antimicrobial activities.   
 
 
 
Figure 25: Xenobiotic biotransformation of compound 7 
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Figure 26: The UV spctrum of compound 8 in MeOH 
Figure 27: The UV spectrum of compound 8 in NaOAc 
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Figure 28: The UV spectrum of compound 8 in MeOH (blue) and in NaOMe (red) 
Figure 29: The UV spectrum of compound 9 in MeOH 
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Figure 30: The UV spectrum of compound 9 in NaOAc 
Figure 31: The UV spectrum of compound 9 in MeOH (blue & pink) and in NaOMe (red) 
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3. Experimental  
 
3.1. General Experimental Procedures 
NMR spectra were recorded on a Varian 400 NMR spectrometer instrument using 
CD3OD and TMS as internal standard, operating at 400 MHz in 1H and 100 MHz in 13C. 
Chemical shifts were reported in δ units and coupling constants (J) in Hz. High-resolution mass 
spectra (HR-ESI-MS) were obtained using a Bruker GioApex 3.0. UV spectra were run on a 
Hewlett Packard 8452A diode array spectrometer.  
 
3.2. Organisms  
Three fungi from the American Type Culture Collection (ATCC) were used in the initial 
screening step for identifying microorganisms that are capable of transforming the compound 7 
to its metabolites. Initial screening was done in 125 ml Erlenmeyer flasks containing 25 ml of 
potato dextrose broth (PDB). A two stage method was used. Our compound was added in 
dimethylsulfoxide (DMSO) at concentration 0.5 mg/ml to 24 h old stage II cultures and 
incubated for 14 days on rotary shaker at 30 Co and 160 rpm.  Samples were taken at 2-d 
intervals. The media was extracted with (CH3)2CHOH: ethyl acetate (2:9).The progress of 
biotransformation was monitored by using precoated Si gel 60 F254 TLC plates with p-
anisaldehyde as the spray reagent.  . One of microorganisms Absidia glauca ATCC 22752 had 
shown good results and was chosen to get the products in large scale.
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3.3. Scale up biotransformation  
Scale up biotransformation was performed in two 2L Erlenmeyer flasks, each containing 
500 mL of potato dextrose broth. The substrate was added to 24 h old stage II cultures at a final 
concentration of 0.5 mg/ml (i.e. 125 mg of substrate was added to each 2 L flask). The same 
environmental conditions described above were used. After 14 days, the cultures were filtrated. 
The filtrate was extract thrice with (CH3)2CHOH: ethyl acetate (2:9) and the organic layer was 
dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. 
 
3.4. Isolation 
The crude extract was fractionated on Sephadex LH-20 with methanol. Eight fractions 
were collected. The fraction containing desired metabolites was purified by high-performance 
liquid chromatography (HPLC, Waters Inc., Milford, MA, Alliance system 2690 separation 
module, Luna C18(2), 5µm column (21.2 mm-250 mm)) connected to a  photodiode  array          
( PDA ) detector. The HPLC mobile phase was water and methanol at flow rate 20ml/min in 
isocratic 30% methanol. 
 
3.5. Antimicrobial Assay 
All organisms are obtained from the American Type Culture Collection (Manassas, VA) 
and include the fungi Candida albicans ATCC 90028, Cryptococcus neoformans ATCC 90113, 
and Aspergillus fumigates ATCC 90906 and the bacteria, methicillin-resistant Staphylococcus 
aureus ATCC 43300 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 
27853, and Mycobacterium intracellulare ATCC 23068. Samples are dissolved in DMSO. 
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DMSO solutions of samples to be tested are diluted in saline and transferred in duplicate to 96 
well microplates.  
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